# Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT): An Immunopathogenic Model of Dysregulated Vaccine-Triggered Immunity

## TL;DR

This paper reviews how certain SARS-CoV-2 vaccines can cause a rare but severe immune disorder called VITT, offering insights into how vaccines might trigger autoimmunity.

## Contribution

The paper proposes an updated immunopathogenic model for VITT, integrating recent findings on antibody persistence and immune mechanisms.

## Key findings

- VITT involves PF4–polyanion complexes inducing anti-PF4 IgG antibodies that activate platelets and drive inflammation.
- Longitudinal studies show a distinction between persistent anti-PF4 antibodies and sustained platelet activation.
- Epidemiological data suggest platform-enriched risk rather than exclusive vaccine causation for VITT.

## Abstract

Background/Objectives: Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare but severe immune-mediated adverse event associated with adenoviral vector-based SARS-CoV-2 vaccines. Beyond its clinical relevance, VITT provides a unique human model of vaccine-triggered autoimmunity and immune-thrombosis. This review critically reassesses the immunopathogenic framework of VITT in light of recent evidence. Methods: We conducted a structured narrative review of studies published between 2021 and 2025, focusing on clinical, epidemiological, and mechanistic data relevant to PF4 immunogenicity, platelet activation, and long-term outcomes. Results: Current evidence supports a multistep model in which adenoviral vector components form immunogenic PF4–polyanion complexes that induce high-affinity anti-PF4 IgG antibodies. These antibodies activate platelets via FcγRIIa, amplify complement signaling, promote neutrophil extracellular trap formation, and drive endothelial perturbation, establishing a self-sustaining thrombo-inflammatory loop. Recent longitudinal studies refine earlier interpretations by distinguishing persistent anti-PF4 seropositivity from sustained platelet-activating capacity. Epidemiological data support platform-enriched risk rather than absolute platform exclusivity, with a proposed mechanistic “border zone” for incomplete phenotypes. Conclusions: VITT represents a tractable human model of vaccine-induced autoimmunity in which innate immune activation and multivalent antigen presentation converge to break tolerance. Updated evidence clarifies antibody persistence, platform enrichment, and translational implications, while highlighting unresolved questions regarding host susceptibility and long-term immune regulation.